BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 2506216)

  • 1. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
    Saffan D; Seibel MM
    Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.
    Martin KA; Hall JE; Adams JM; Crowley WF
    J Clin Endocrinol Metab; 1993 Jul; 77(1):125-9. PubMed ID: 8325934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Filicori M; Flamigni C; Campaniello E; Meriggiola MC; Michelacci L; Valdiserri A; Ferrari P
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1737-42. PubMed ID: 2122730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism.
    Blunt SM; Butt WR
    Acta Endocrinol Suppl (Copenh); 1988; 288():58-65. PubMed ID: 3138867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a specific role of GnRH pulse frequency in the control of the human menstrual cycle.
    Filicori M; Flamigni C; Campaniello E; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A; Valdiserri A
    Am J Physiol; 1989 Dec; 257(6 Pt 1):E930-6. PubMed ID: 2514600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exaggerated free alpha-subunit levels during pulsatile gonadotropin-releasing hormone replacement in women with idiopathic hypogonadotropic hypogonadism.
    Lavoie HB; Martin KA; Taylor E; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 1998 Jan; 83(1):241-7. PubMed ID: 9435449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: effects of dosage.
    Santoro N; Wierman ME; Filicori M; Waldstreicher J; Crowley WF
    J Clin Endocrinol Metab; 1986 Jan; 62(1):109-16. PubMed ID: 3079597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone.
    Schachter M; Balen AH; Patel A; Jacobs HS
    Gynecol Endocrinol; 1996 Oct; 10(5):327-35. PubMed ID: 8915662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles.
    Filicori M; Flamigni C; Dellai P; Cognigni G; Michelacci L; Arnone R; Sambataro M; Falbo A
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1215-20. PubMed ID: 7962297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
    Couzinet B; Young J; Brailly S; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
    Rossmanith WG; Wirth U; Benz R; Wolf AS
    Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.
    Corenthal L; Von Hagen S; Larkins D; Ibrahim J; Santoro N
    Fertil Steril; 1994 Jun; 61(6):1027-33. PubMed ID: 8194612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.
    Couzinet B; Young J; Kujas M; Meduri G; Brailly S; Thomas JL; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4191-6. PubMed ID: 10566671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction of ovulation with pulsatile LHRH in anovulatory women].
    Masaoka K; Kumasaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):937-46. PubMed ID: 6431037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
    Lubin V; Charbonnel B; Bouchard P
    Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.